0001209191-14-002646.txt : 20140109
0001209191-14-002646.hdr.sgml : 20140109
20140109164915
ACCESSION NUMBER: 0001209191-14-002646
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140107
FILED AS OF DATE: 20140109
DATE AS OF CHANGE: 20140109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SALIX PHARMACEUTICALS LTD
CENTRAL INDEX KEY: 0001009356
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943267443
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8510 COLONNADE CENTER DRIVE
CITY: RALEIGH
STATE: NC
ZIP: 27615
BUSINESS PHONE: (919) 862-1000
MAIL ADDRESS:
STREET 1: 8510 COLONNADE CENTER DRIVE
CITY: RALEIGH
STATE: NC
ZIP: 27615
FORMER COMPANY:
FORMER CONFORMED NAME: SALIX HOLDINGS LTD
DATE OF NAME CHANGE: 19970807
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KEANE WILLIAM P
CENTRAL INDEX KEY: 0001204286
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23265
FILM NUMBER: 14519257
MAIL ADDRESS:
STREET 1: C/O SALIX PHARMACEUTICALS, LTD.
STREET 2: 8510 COLONNADE CENTER DRIVE
CITY: RALEIGH
STATE: NC
ZIP: 27615
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2014-01-07
0
0001009356
SALIX PHARMACEUTICALS LTD
SLXP
0001204286
KEANE WILLIAM P
8510 COLONNADE CENTER DRIVE
RALEIGH
NC
27615
1
0
0
0
Common Stock
2014-01-07
4
M
0
22500
18.8733
A
57740
D
Common Stock
2014-01-07
4
S
0
22500
88.31
D
35240
D
Option to Buy Common Stock
18.8733
2014-01-07
4
M
0
22500
0.00
D
2014-06-17
Common Stock
22500
0
D
Option to Buy Common Stock
17.63
2015-06-09
Common Stock
15000
15000
D
The exercise and sale were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2013.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.93 to $88.88, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Options are 100% vested.
/s/ William P. Keane
2014-01-09